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Case Report
Pulmonary Embolism and Giant Cavitary Lesion
Developing After COVID-19 Pneumonia
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The clinical manifestations of the worldwide pandemic, which began in mainland China in
December 2019, were very similar to viral pneumonia and defined as Coronavirus disease
2019 (COVID-19). Complications such as acute respiratory distress syndrome (ARDS), acute
cardiac tissue damage, secondary infections, isolated coagulopathy and pulmonary embolism have been reported with COVID-19 disease.
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Clinical Findings

A 79-year-old woman admitted to the emergency room (ER) had complaints of fever and
cough. The patient was admitted to the ER with the suspicion of COVID-19. Samples were
collected with a nasopharyngeal swab and confirmed as COVID-19. In addition, a chest CT
examination was performed. In the first evaluation after admittance, the D-dimer value was
measured as 450 μg/L. In the follow-up of the patient, on the 18th day, increased respiratory
distress and high D-dimer level (7893 μg/L) were detected in the laboratory findings.

Outcomes

A chest CT scan had ground-glass opacities compatible with COVID-19 pneumonia. A giant
cavitary lesion was detected following the development of pulmonary embolism after
COVID-19 disease.

Conclusions

In rare cases of COVID-19 cavitation development may occur after pulmonary infarction. In
addition, it should be remembered that emphysema, giant bulla and pneumothorax may
develop in COVID-19 pneumonia cases undergoing HFNC oxygen therapy. We present a case
of a giant cavitary lesion that developed following a COVID-19-related pulmonary embolism.
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Introduction

In December 2019, several unexplained cases
of pneumonia were reported in Wuhan, Hubei
Province, China. Clinical findings were very
similar to viral pneumonia. A new coronavirus
was identified as a pathogen by examining the
samples taken from the respiratory tract of patients and the disease was named Coronavirus
Disease 2019 (COVID-19). The patients shared
common symptoms such as fever, cough,
muscle pain and fatigue. Thoracic CT scans of
the patients demonstrated findings consis-

tent with viral pneumonia. The most common
CT features of the viral pneumonia were pure
ground-glass opacities (GGO), GGO with consolidation, rounded opacities, linear opacities,
bronchiolar wall thickening and interlobular
septal thickening. Complications such as acute
respiratory distress syndrome (ARDS), acute
cardiac tissue damage, secondary infections,
isolated coagulopathy and pulmonary embolism have been reported with COVID-19 disease.1-3 Acute pulmonary embolism (PE) causes
pulmonary infarction in only 10% of cases due
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to the dual blood supply to the lungs.4 Cavitation can occur in 4–7% of cases of pulmonary
infarction.5 The development of a pulmonary
infarction larger than 4 cm is a strong risk
factor for aseptic necrosis, which may lead to
the development of cavitation.6 Some patients
with cavitation may develop an abscess. These
patients classically present complaints such as
fever, leukocytosis and sputum production. We
present a case of a giant cavitary lesion that
developed following a COVID-19-related pulmonary embolism.

Case Presentation

A 79-year-old woman was admitted to the
emergency room with fever and dry cough
complaints, which she had for three days. A
nasopharyngeal swab was used to collect a
sample for a Reverse-Transcriptase Polymerase
Chain Reaction (RT-PCR) to detect COVID-19.
When the patient developed dyspnea accompanied by hypoxemia, a thoracic CT scan was
performed. In addition, due to faster results
during the COVID-19 pandemic, patients with
dyspnea were given chest CT examinations. Her
exam revealed ground-glass opacities compatible with COVID-19 pneumonia, consolidation
in the left lower lobe, and a pleural effusion on
the left lobe. The patient’s RT-PCR test result
returned positive, confirming the suspected
diagnosis of COVID-19. In the first evaluation
after acceptance, the D-dimer value was measured as 450 μg/L.

Patchy ground-glass infiltrates were observed
in the right upper lobe on the patient’s first
non-contrast thoracic CT on day 1. During the
follow-up with the patient on day 18, a significantly elevated d-dimer level of 7893 μg/L was
detected with worsening respiratory distress.
In the PCTA examination performed on the
18th day, a 15-mm diameter, thin-walled air cyst
in the anterior right lobe, a pulmonary embolus
and ground-glass opacities were present. Also,
PCTA demonstrated an acute thromboembolism was extending from both main pulmonary
arteries to the lobar arteries. (Figure 1) In addition to COVID-19 treatment the patient was
started on anticoagulant therapy for pulmonary
embolism. During this period, high-flow nasal
cannula (HFNC) oxygen therapy was initiated
due to respiratory distress. In the follow-up
scan performed on day 25, a giant cavitary
lesion with an axial diameter exceeding 80 mm
and thick walls surrounded by consolidation
and ground-glass opacities were found in the
right upper lobe anterior segment. (Figure 2)
In addition, the new scan showed an increase
in the left-sided pleural effusion and a newly
developed pleural effusion on the right side.
The atelectasis observed in the left lower lobe
increased. It was determined that the general
condition of the patient was not suitable for
advanced treatment planning. Her condition
rapidly deteriorated and she was taken to the
intensive care unit for tracheal intubation and
ventilator support but died a short time later.

Figure 1. Axial CT angiography scan of the chest shows bilateral filling defects (white arrows) in
both pulmonary arteries, representing thrombi.
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Figure 2. CT scans of 79-year-old woman who presented with fever and cough. A (Day 1) normal
lung parenchyma, B (Day 18) small air cyst with ground-glass opacities and C (Day 25) giant cavitary lesion in the right upper lobe.

Discussion

Previous studies show that COVID-19 disease
may have a poor prognosis with thromboembolic complications in patients with low platelet levels, increased D-dimer levels, increased
prothrombin levels and significant comorbidity.7 D-dimer levels higher than 1000 μg/L in
COVID-19 patients have been identified as
an important risk factor for mortality.8 In our
patient who was confirmed to have COVID-19
disease, an increase in D-dimer levels, acute
PE development and acute giant cavitary
lesion development in the lung parenchyma
are observed. Although the cavitary lesion had
thick walls and areas of consolidation in the
surrounding parenchyma, there was no extensive consolidation/atelectasis compatible with
the infarction in the surrounding parenchyma.
Pulmonary infarction, which can develop after
a pulmonary embolism, can cause cavitation
development. In addition, factors such as old
age, heart failure and chronic lung disease are
reported as risk factors for the development of
cavitation.5 Infected infarction leads to faster
cavitation than infarcts with aseptic necrosis. In
our case, the secondary infection was not considered due to thick-walled cavitary lesion and
limited consolidation around it, as there was no
significant fluid accumulation in it. However,
aspiration and culture were not possible due to
the rapid deterioration in the patient’s condition.

Sun et al. reported the development of a giant
bulla in a patient with COVID-19 pneumonia.9
It is noted that, like our patient, COVID-19
patients who received HFNC oxygen therapy
could develop giant bulla and pneumothorax
with alveolar rupture. In our case, the origin of
the giant cavitary lesion is not known exactly,
but in the second scan, it was thought that
it should be evaluated as a giant bulla due to
the development of a thin-walled cyst and
subsequent giant cystic cavitary lesion. However, pulmonary infarction and cavitary lesion
development may also occur after pulmonary
embolism. High mortality rates are reported
for cavitations associated with pulmonary
infarction, whether infected or not.10 Clinicians
fighting the COVID-19 outbreak should consider the increased risk of thromboembolic complications. PE development in COVID-19 is common, especially in cases with pneumonia.11 In
rare cases of COVID-19, cavitation development
may occur after pulmonary infarction. In addition, it should be remembered that emphysema, giant bulla and pneumothorax may develop
in COVID-19 pneumonia patients undergoing
HFNC oxygen therapy.
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